+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
ID05086614

Study of Thymosin-alpha 1 as Additional Treatment After Surgery for High-risk Stage II and III Colorectal Cancer

Led by Fudan University · Updated on 2021-10-21

2500

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating thymosin-alpha 1 as an additional treatment for patients with high-risk stage II and stage III colorectal cancer who have undergone radical surgery. Despite surgery and postoperative chemotherapy or radiotherapy, 30-40% of these patients experience cancer recurrence or spread. This study aims to verify the safety and effects of thymosin-alpha 1 in helping to improve immune response and potentially reduce cancer recurrence and metastasis. Participants are randomly assigned to one of two groups one group receives thymosin-alpha 1 injections twice a week for six months after surgery, while the other group does not receive this treatment. Both groups continue to receive chemotherapy or radiotherapy according to standard Chinese guidelines. The main goal is to compare the disease-free survival rate over three years between the groups. During the study, participants will be monitored regularly for outcomes such as cancer recurrence, overall survival, and any side effects related to thymosin-alpha 1 treatment over a six-month period. The total study duration includes a three-year follow-up to assess long-term effects. Patients will undergo clinical assessments and tests to evaluate their health and response to treatment throughout the study period.

CONDITIONS

Brief Title

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Research Team

J

Jianmin Xu, Dr.

Q

Qingyang Feng, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here